Dinaciclib synergizes with <scp>BH3</scp> mimetics targeting <scp>BCL</scp>‐2 and <scp>BCL‐X<sub>L</sub></scp> in multiple myeloma cell lines partially dependent on <scp>MCL</scp>‐1 and in plasma cells from patients
Molecular oncology